Roger S McIntyre1, Hanna O Woldeyohannes2, Joanna K Soczynska3, Maj Vinberg4, Danielle S Cha3, Yena Lee2, Laura A Gallaugher2, Roman S Dale5, Mohammad T Alsuwaidan2, Rodrigo B Mansur2, David J Muzina6, Andre Carvalho7, Sidney Kennedy8. 1. Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, 399 Bathurst Street, Toronto, ON M5T 2S8, Canada. 2. Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada. 3. Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada, and Institute of Medical Science, University of Toronto, Toronto, ON, Canada. 4. Department of Psychiatry, Psychiatric Center, University of Copenhagen, Copenhagen, Denmark. 5. Cleveland Clinic, Cleveland, OH, USA. 6. Medco Health Solutions, Inc., Fort Worth, TX, USA. 7. Translational Psychiatry Research Group and Department of Clinical Medicine, Federal University of Ceara, Fortaleza, Brazil. 8. Department of Psychiatry, University of Toronto, Toronto, ON, Canada, and Institute of Medical Science, University of Toronto, Toronto, ON, Canada.
Abstract
OBJECTIVES: The aim of the study was to evaluate the prevalence of and illness characteristics in adults with major depressive disorder (MDD) with anxious distress specifier (ADS) enrolled in the International Mood Disorders Collaborative Project, which is a collaborative research platform at the Mood Disorders Psychopharmacology Unit, University of Toronto, Canada and the Cleveland Clinic, Cleveland, Ohio, USA. METHODS: Data from participants who met criteria for a current major depressive episode as part of MDD (n = 830) were included in this post hoc analysis. Diagnostic and Statistical Manual Version-5-defined ADS was operationalized as the presence of at least two out of three proxy items instead of two out of five specifiers. RESULTS: A total of 464 individuals (i.e. 56%) met criteria for ADS. There were no between-group differences in sociodemographic variables (e.g. gender, employment, marital status). Greater severity of illness was observed in adults with ADS as evidenced by a higher number of hospitalizations, higher rates of suicidal ideation, greater depressive symptom severity, greater workplace impairment, decreased quality of life, and greater self-reported cognitive impairment. CONCLUSIONS: Our findings underscore the importance of evaluating ADS in adults with MDD as its presence identifies a subpopulation with greater illness-associated burden and hazards.
OBJECTIVES: The aim of the study was to evaluate the prevalence of and illness characteristics in adults with major depressive disorder (MDD) with anxious distress specifier (ADS) enrolled in the International Mood Disorders Collaborative Project, which is a collaborative research platform at the Mood Disorders Psychopharmacology Unit, University of Toronto, Canada and the Cleveland Clinic, Cleveland, Ohio, USA. METHODS: Data from participants who met criteria for a current major depressive episode as part of MDD (n = 830) were included in this post hoc analysis. Diagnostic and Statistical Manual Version-5-defined ADS was operationalized as the presence of at least two out of three proxy items instead of two out of five specifiers. RESULTS: A total of 464 individuals (i.e. 56%) met criteria for ADS. There were no between-group differences in sociodemographic variables (e.g. gender, employment, marital status). Greater severity of illness was observed in adults with ADS as evidenced by a higher number of hospitalizations, higher rates of suicidal ideation, greater depressive symptom severity, greater workplace impairment, decreased quality of life, and greater self-reported cognitive impairment. CONCLUSIONS: Our findings underscore the importance of evaluating ADS in adults with MDD as its presence identifies a subpopulation with greater illness-associated burden and hazards.
Entities:
Keywords:
Diagnostic and Statistical Manual Version-5; anxious distress specifier; major depressive disorder
Authors: Ayal Schaffer; Diane McIntosh; Benjamin I Goldstein; Neil A Rector; Roger S McIntyre; Serge Beaulieu; Richard Swinson; Lakshmi N Yatham Journal: Ann Clin Psychiatry Date: 2012-02 Impact factor: 1.567
Authors: Roger S McIntyre; Joanna Z Soczynska; Hanna O Woldeyohannes; Mohammad T Alsuwaidan; Danielle S Cha; André F Carvalho; Jeanette M Jerrell; Roman M Dale; Laura A Gallaugher; David J Muzina; Sidney H Kennedy Journal: Compr Psychiatry Date: 2014-08-23 Impact factor: 3.735
Authors: Maurizio Fava; Jonathan E Alpert; Cheryl N Carmin; Stephen R Wisniewski; Madhukar H Trivedi; Melanie M Biggs; Kathy Shores-Wilson; Don Morgan; Terry Schwartz; G K Balasubramani; A John Rush Journal: Psychol Med Date: 2004-10 Impact factor: 7.723
Authors: Maurizio Fava; A John Rush; Jonathan E Alpert; G K Balasubramani; Stephen R Wisniewski; Cheryl N Carmin; Melanie M Biggs; Sidney Zisook; Andrew Leuchter; Robert Howland; Diane Warden; Madhukar H Trivedi Journal: Am J Psychiatry Date: 2008-01-02 Impact factor: 18.112
Authors: Roger S McIntyre; Danielle S Cha; Joanna K Soczynska; Hanna O Woldeyohannes; Laura Ashley Gallaugher; Paul Kudlow; Mohammad Alsuwaidan; Anusha Baskaran Journal: Depress Anxiety Date: 2013-03-06 Impact factor: 6.505
Authors: Lisanne M Jenkins; Jonathan P Stange; Katie L Bessette; Yi-Shin Chang; Samantha D Corwin; Kristy A Skerrett; Víctor G Patrón; Jon-Kar Zubieta; Natania A Crane; Alessandra M Passarotti; Daniel S Pine; Scott A Langenecker Journal: J Affect Disord Date: 2018-08-01 Impact factor: 4.839
Authors: Aldemara I Silva; Victor A D Holanda; Joaquim G Azevedo Neto; Edilson D Silva Junior; Vanessa P Soares-Rachetti; Girolamo Calo; Chiara Ruzza; Elaine C Gavioli Journal: Psychopharmacology (Berl) Date: 2020-02-24 Impact factor: 4.530
Authors: Michael E Thase; Emmanuelle Weiller; Peter Zhang; Catherine Weiss; Roger S McIntyre Journal: Neuropsychiatr Dis Treat Date: 2018-12-20 Impact factor: 2.570
Authors: Roxanne Gaspersz; Femke Lamers; Gayle Wittenberg; Aartjan T F Beekman; Albert M van Hemert; Robert A Schoevers; Brenda W J H Penninx Journal: Transl Psychiatry Date: 2017-12-08 Impact factor: 6.222
Authors: Anthony J Rosellini; Michelle L Bourgeois; Jeannette Correa; Esther S Tung; Svetlana Goncharenko; Timothy A Brown Journal: J Psychiatr Res Date: 2018-05-08 Impact factor: 4.791
Authors: Ella J Daly; Ibrahim Turkoz; Giacomo Salvadore; Maggie Fedgchin; Dawn F Ionescu; H Lynn Starr; Stephane Borentain; Madhukar H Trivedi; Michael E Thase; Jaskaran B Singh Journal: Depress Anxiety Date: 2021-07-22 Impact factor: 8.128